BCL-2 is universally over-expressed in CLL cells [11], enabling them to evade apoptosis and accumulate in vivo, making CLL the ideal disease in which to test the clinical utility of venetoclax [12,13,14,15]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.